Radiotherapy plus trastuzumab in the treatment of Her2-positive locally advanced breast cancer

被引：0
|
作者：
Belokhvostova, A. [1 ]
Ragulin, Y. [1 ]
机构：
[1] Hertsen Fed Med Res Ctr, A Cyb Sci Res Ctr Radiol, Thorac Dept, Obninsk, Russia
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
10.1093/annonc/mdv114.2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] The effect of trastuzumab on pCR in locally advanced HER2-positive breast cancer.
    Lavasani, S. M.
    Pritchard, K. I.
    Kiss, A.
    Verma, S.
    Wright, F.
    Boileau, J.
    Trudeau, M. E.
    Czarnota, G. J.
    Dent, R. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (27)
  • [2] Trastuzumab plus Paclitaxel in HER2-positive Breast Cancer
    不详
    GYNAKOLOGE, 2016, 49 (08): : 558 - 558
  • [3] Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
    Verma, Sunil
    Miles, David
    Gianni, Luca
    Krop, Ian E.
    Welslau, Manfred
    Baselga, Jose
    Pegram, Mark
    Oh, Do-Youn
    Dieras, Veronique
    Guardino, Ellie
    Fang, Liang
    Lu, Michael W.
    Olsen, Steven
    Blackwell, Kim
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (19): : 1783 - 1791
  • [4] Safety of pertuzumab plus trastuzumab plus vinorelbine for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer
    Perez, E. A.
    Lopez-Vega, J. M.
    Del Mastro, L.
    Petit, T.
    Zamagni, C.
    Freudensprung, U.
    Bastiere-Truchot, L.
    Walker, R.
    Andersson, M.
    CANCER RESEARCH, 2013, 73
  • [5] Neratinib plus capecitabine for the treatment of advanced HER2-positive breast cancer
    Oliveira, Mafalda
    Garrigos, Laia
    Assaf, Juan David
    Escriva-de-Romani, Santiago
    Saura, Cristina
    EXPERT REVIEW OF ANTICANCER THERAPY, 2020, 20 (09) : 731 - 741
  • [6] Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
    Romond, EH
    Perez, EA
    Bryant, J
    Suman, VJ
    Geyer, CE
    Davidson, NE
    Tan-Chiu, E
    Martino, S
    Paik, S
    Kaufman, PA
    Swain, SM
    Pisansky, TM
    Fehrenbacher, L
    Kutteh, LA
    Vogel, VG
    Visscher, DW
    Yothers, G
    Jenkins, RB
    Brown, AM
    Dakhil, SR
    Mamounas, EP
    Lingle, WL
    Klein, PM
    Ingle, JN
    Wolmark, N
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16): : 1673 - 1684
  • [7] TRASTUZUMAB EMTANSINE FOR THE TREATMENT OF HER2-POSITIVE METASTATIC BREAST CANCER
    Haddley, K.
    DRUGS OF TODAY, 2013, 49 (11) : 701 - 715
  • [8] Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer
    Oostra, Drew R.
    Macrae, Erin R.
    BREAST CANCER-TARGETS AND THERAPY, 2014, 6 : 103 - 113
  • [9] Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
    Veeraraghavan, Jamunarani
    Gutierrez, Carolina
    Sethunath, Vidyalakshmi
    Mehravaran, Sepideh
    Giuliano, Mario
    Shea, Martin J.
    Mitchell, Tamika
    Wang, Tao
    Nanda, Sarmistha
    Pereira, Resel
    Davis, Robert
    Goutsouliak, Kristina
    Qin, Lanfang
    De Angelis, Carmine
    Diala, Irmina
    Lalani, Alshad S.
    Nagi, Chandandeep
    Hilsenbeck, Susan G.
    Rimawi, Mothaffar F.
    Osborne, C. Kent
    Schiff, Rachel
    NPJ BREAST CANCER, 2021, 7 (01)
  • [10] NICE guidance on trastuzumab emtansine for HER2-positive advanced breast cancer
    Elsada, Ahmed
    Doss, Sally
    Robertson, Janet
    Adam, E. Jane
    LANCET ONCOLOGY, 2016, 17 (02): : 143 - 144
12345